Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival ...

First-line treatment with sunvozertinib significantly prolongs PFS compared to chemotherapy in advanced or metastatic NSCLC with EGFR insertions.

Add-on tafasitamab and lenalidomide did not negatively impact chemotherapy backbone ...

Bristol Myers Squibb may be leading the way when it comes to pursuing cereblon E3 ligase modulator (CELMoD) drugs, but today, the pharma is standing tall.  | Bristol Myers Squibb may have gone big in ...

Higher rates of adverse events offset the positive survival results in an area of great unmet need. For decades, the standard ...

Please provide your email address to receive an email when new articles are posted on . The addition of pyrotinib to trastuzumab and docetaxel improved 4-year OS vs. placebo for patients with ...

The Personal Financial Specialist (PFS) certification helps Certified Public Accountants (CPAs) demonstrate an expertise in all aspects of wealth management. A PFS is someone with a CPA who also ...

Neuropathy, skin rash, and hyperglycemia are linked to improved PFS in patients treated with enfortumab vedotin for metastatic urothelial carcinoma. Patients experiencing these side effects had longer ...

Progression-free survival (PFS) in relapsed multiple myeloma almost doubled with the addition of the CD38 inhibitor isatuximab (Sarclisa) to a standard proteasome inhibitor (PI) regimen, according to ...

Regeneron’s phase 3 trial of the LAG-3 inhibitor fianlimab plus cemiplimab failed to meet its primary endpoint of progression-free survival in first-line advanced melanoma.